A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC



Status:Recruiting
Conditions:Lung Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:5/3/2018
Start Date:February 2015
End Date:December 2018

Use our guide to learn which trials are right for you!

SHERLOC: A Phase 2 Study of MM-121 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is
more effective than docetaxel alone in regards to PFS in patients with heregulin-positive
NSCLC.

This study is a randomized, open-label, international, multi-center, phase 2 study in
patients with Heregulin-positive NSCLC histologically classified as adenocarcinoma that have
progressed following no more than two systemic therapies for locally advanced or metastatic
disease, one of which must have been a platinum containing regimen. All patients will
initially be screened for heregulin status. Eligible patients will be randomized to receive
MM-121 in combination with docetaxel versus docetaxel alone.

Inclusion Criteria:

- Patients with a diagnosis of cytologically or histologically documented adenocarcinoma
of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC
disease not amenable to surgery with curative intent

- Not received more than 2 prior systemic therapies- one of which must have been a
platinum based regimen- for primary or recurrent disease

- Tissue submitted for HRG-biomarker testing

- ECOG performance status (PS) of 0 or 1

Exclusion Criteria:

- Known ALK mutation

- Presence of exon 19 deletion or exon 21 (L858R) substitution of the EGFR gene

- Received >2 prior systemic anti-cancer drug regimen for locally advanced disease

- Prior treatment with an anti-ErbB3 antibody

- CTCAE grade 3 or higher peripheral neuropathy

- Symptomatic CNS metastases or CNS metastases requiring steroids

- Any other active malignancy requiring systemic therapy

- Clinically significant cardiac disease
We found this trial at
18
sites
Pittsburgh, Pennsylvania
Phone: 412-578-5393
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Boston, Massachusetts
Phone: 617-632-7889
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bronx, New York
Phone: 718-405-8539
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Chicago, Illinois
Phone: 312-926-4248
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Danvers, Massachusetts 01923
Phone: 978-882-6034
?
mi
from
Danvers, MA
Click here to add this to my saved trials
Fairfax, Virginia 22031
Phone: 571-389-0873
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
Lafayette, Indiana 47904
Phone: 765-446-5111
?
mi
from
Lafayette, IN
Click here to add this to my saved trials
Los Angeles, California
Phone: 323-865-0421
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Nashville, Tennessee 37232
Phone: 800-811-8480
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New York, New York 10032
Phone: 212-731-5111
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania
Phone: 215-728-2586
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Santa Rosa, California 95405
Phone: 707-521-3814
?
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Seattle, Washington 98105
Phone: 206-342-6926
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tampa, Florida
Phone: 813-745-4625
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Toronto, Ontario
Phone: (416) 581-7804
?
mi
from
Toronto,
Click here to add this to my saved trials
Tucson, Arizona 85724
Phone: 520-290-2510
?
mi
from
Tucson, AZ
Click here to add this to my saved trials